maintenance car - PMC

Sabine Heitzeneder, Kristopher R. Bosse, Zhongyu Zhu, Doncho Zhelev, Robbie G. Majzner, Molly T. Radosevich, Shaurya Dhingra, Elena Sotillo, Samantha Buongervino, Guillem Pascual-Pasto, Emily Garrigan, Peng Xu, Jing Huang, Benjamin Salzer, Alberto Delaidelli, Swetha Raman, Hong Cui, Benjamin Martinez, Scott J. Bornheimer, Bita Sahaf, Anya Alag, Irfete S. Fetahu, Martin Hasselblatt, Kevin R. Parker, Hima Anbunathan, Jennifer Hwang, Min Huang, Kathleen Sakamoto, Norman J. Lacayo, Dorota D. Klysz, Johanna Theruvath, José G. Vilches-Moure, Ansuman T. Satpathy, Howard Y. Chang, Manfred Lehner, Sabine Taschner-Mandl, Jean-Phillipe Julien, Poul H. Sorensen, Dimiter S. Dimitrov, John M. Maris, Crystal L. Mackall

Cancer Cell. Author manuscript; available in PMC 2023 Jan 10.

Published in final edited form as: Cancer Cell. 2022 Jan 10; 40(1): 53–69.e9. Published online 2021 Dec 30. doi: 10.1016/j.ccell.2021.12.005

PMCID:: PMC9092726

Article PDF–3.7M

Select item 98459258.

“Even more than that, men love cars”: “Car guy” memes and hegemonic masculinity

Lauren Dundes

Front Sociol. 2022; 7: 1034669. Published online 2023 Jan 4. doi: 10.3389/fsoc.2022.1034669

PMCID:: PMC9845925

Article PDF–1.1M

Select item 102785999.

Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours

Christian L. Flugel, Robbie G. Majzner, Giedre Krenciute, Gianpietro Dotti, Stanley R. Riddell, Dimitrios L. Wagner, Mohamed Abou-el-Enein

Nat Rev Clin Oncol. Author manuscript; available in PMC 2023 Jul 1.

Published in final edited form as: Nat Rev Clin Oncol. 2023 Jan; 20(1): 49–62. Published online 2022 Nov 23. doi: 10.1038/s41571-022-00704-3

PMCID:: PMC10278599

Article PDF–1.9M

Select item 1064680210.

Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the acute myeloid leukemia burden

Marta Biondi, Sarah Tettamanti, Stefania Galimberti, Beatrice Cerina, Chiara Tomasoni, Rocco Piazza, Samantha Donsante, Simone Bido, Vincenzo Maria Perriello, Vania Broccoli, Andrea Doni, Francesco Dazzi, Alberto Mantovani, Gianpietro Dotti, Andrea Biondi, Alice Pievani, Marta Serafini

Blood. 2023 May 25; 141(21): 2587–2598. Published online 2023 Feb 16. doi: 10.1182/blood.2022018330

PMCID:: PMC10646802

Article

Select item 902469411.

Development of CAR T Cell Therapy in Children—A Comprehensive Overview

Michael Boettcher, Alexander Joechner, Ziduo Li, Sile Fiona Yang, Patrick Schlegel

J Clin Med. 2022 Apr; 11(8): 2158. Published online 2022 Apr 12. doi: 10.3390/jcm11082158

PMCID:: PMC9024694

Article PDF–2.6M

Select item 575101012.

Integrating Norm Activation Model and Theory of Planned Behavior to Understand Sustainable Transport Behavior: Evidence from China

Yuwei Liu, Hong Sheng, Norbert Mundorf, Colleen Redding, Yinjiao Ye

Int J Environ Res Public Health. 2017 Dec; 14(12): 1593. Published online 2017 Dec 18. doi: 10.3390/ijerph14121593

PMCID:: PMC5751010

Article PDF–741K

Select item 1037288113.

Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity

Leyuan Ma, Alexander Hostetler, Duncan M. Morgan, Laura Maiorino, Ina Sulkaj, Charles A. Whittaker, Alexandra Neeser, Ivan Susin Pires, Parisa Yousefpour, Justin Gregory, Kashif Qureshi, Jonathan Dye, Wuhbet Abraham, Heikyung Suh, Na Li, J. Christopher Love, Darrell J. Irvine

Cell. Author manuscript; available in PMC 2023 Jul 27.

Published in final edited form as: Cell. 2023 Jul 20; 186(15): 3148–3165.e20. Published online 2023 Jul 5. doi: 10.1016/j.cell.2023.06.002

PMCID:: PMC10372881

Article PDF–3.0M

Select item 569672814.

Prospects for combined use of oncolytic viruses and CAR T-cells

Adam Ajina, John Maher

J Immunother Cancer. 2017; 5: 90. Published online 2017 Nov 21. doi: 10.1186/s40425-017-0294-6

PMCID:: PMC5696728

Article PDF–6.4M

Select item 945408615.

Production and characterization of virus-free, CRISPR-CAR T cells capable of inducing solid tumor regression

Katherine P Mueller, Nicole J Piscopo, Matthew H Forsberg, Louise A Saraspe, Amritava Das, Brittany Russell, Madeline Smerchansky, Dan Cappabianca, Lei Shi, Keerthana Shankar, Lauren Sarko, Namita Khajanchi, Nina La Vonne Denne, Apoorva Ramamurthy, Adeela Ali, Cicera R Lazzarotto, Shengdar Q Tsai, Christian M Capitini, Krishanu Saha

J Immunother Cancer. 2022; 10(9): e004446. Published online 2022 Sep 5. doi: 10.1136/jitc-2021-004446

PMCID:: PMC9454086

Article PDF–9.1M

Select item 1106291816.

FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy

Jack D. Chan, Christina M. Scheffler, Isabelle Munoz, Kevin Sek, Joel N. Lee, Yu-Kuan Huang, Kah Min Yap, Nicole Y. L. Saw, Jasmine Li, Amanda X. Y. Chen, Cheok Weng Chan, Emily B. Derrick, Kirsten L. Todd, Junming Tong, Phoebe A. Dunbar, Jiawen Li, Thang X. Hoang, Maria N. de Menezes, Emma V. Petley, Joelle S. Kim, Dat Nguyen, Patrick S. K. Leung, Joan So, Christian Deguit, Joe Zhu, Imran G. House, Lev M. Kats, Andrew M. Scott, Benjamin J. Solomon, Simon J. Harrison, Jane Oliaro, Ian A. Parish, Kylie M. Quinn, Paul J. Neeson, Clare Y. Slaney, Junyun Lai, Paul A. Beavis, Phillip K. Darcy

Nature. 2024; 629(8010): 201–210. Published online 2024 Apr 10. doi: 10.1038/s41586-024-07242-1

PMCID:: PMC11062918

Article PDF–23M

Select item 997577017.

Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy

Alfred L. Garfall, Adam D. Cohen, Sandra P. Susanibar-Adaniya, Wei-Ting Hwang, Dan T. Vogl, Adam J. Waxman, Simon F. Lacey, Vanessa E. Gonzalez, Joseph A. Fraietta, Minnal Gupta, Irina Kulikovskaya, Lifeng Tian, Fang Chen, Natalka Koterba, Robert L. Bartoszek, Margaret Patchin, Rong Xu, Gabriela Plesa, Don L. Siegel, Andrea Brennan, Anne Marie Nelson, Regina Ferthio, Angela Cosey, Kim-Marie Shea, Rachel Leskowitz, Megan Four, Wesley V. Wilson, Fei Miao, Eric Lancaster, Beatriz M. Carreno, Gerald P. Linette, Elizabeth O. Hexner, Regina M. Young, Dexiu Bu, Keith G. Mansfield, Jennifer L. Brogdon, Carl H. June, Michael C. Milone, Edward A. Stadtmauer

Blood Cancer Discov. 2023 Mar 1; 4(2): 118–133. Published online 2022 Nov 21. doi: 10.1158/2643-3230.BCD-22-0074

PMCID:: PMC9975770

Article PDF–10M

Select item 999672018.

Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse Following Stem Cell Transplant

Qing Li, Cuicui Lyu, Meijing Liu, Jia Wang, Nan Mou, Erlie Jiang, Rongli Zhang, Qi Deng

Cell Transplant. 2023 Jan-Dec; 32: 09636897231158155. Published online 2023 Mar 6. doi: 10.1177/09636897231158155

PMCID:: PMC9996720

Article PDF–2.8M

Select item 515508719.

Airborne Infectious Agents and Other Pollutants in Automobiles for Domestic Use: Potential Health Impacts and Approaches to Risk Mitigation

Syed A. Sattar, Kathryn E. Wright, Bahram Zargar, Joseph R. Rubino, M. Khalid Ijaz

J Environ Public Health. 2016; 2016: 1548326. Published online 2016 Nov 30. doi: 10.1155/2016/1548326

PMCID:: PMC5155087

Article PDF–826K

Select item 1076506520.

IL-21-armored B7H3 CAR-iNKT cells exert potent antitumor effects

Yilin Liu, Yuanyuan Dang, Chuhan Zhang, Liu Liu, Wenhui Cai, Liantao Li, Lin Fang, Meng Wang, Shunzhe Xu, Gang Wang, Junnian Zheng, Huizhong Li

iScience. 2024 Jan 19; 27(1): 108597. Published online 2023 Nov 30. doi: 10.1016/j.isci.2023.108597

PMCID:: PMC10765065

Article PDF–6.9M

<< First< Prev

Page of 2357

Next >Last >>

Supplemental Content

Filter your results:

Manage Filters

PMC Images search for maintenance car

Figure 3Armored CAR T-cells genetically engineered to constitutively express 4-1BBL

CAR T-cells constitutively expressing 4-1BBL improve CAR T anti-tumour efficacy by potentially modulating the tumour microenvironment via enhancement of DC IL-12 secretion, transcostimulation of endogenous T-cells and central memory maintenance.

Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy

Biochem Soc Trans. ;44(2):412-418.
Figure 4.Maintenance of the TCF7 network among effector T-cells associates with long CAR T-cell persistence.

(A) Volcano plot displaying differentially expressed genes in T_EM and T_EFF between patients with long-term (≥ 6 months) vs failed (< 6 months) CAR T-cell persistence. (B) Volcano plot displaying differentially expressed transcription factors in T_EM and T_EFF between patients with long-term (≥ 6 months) vs failed (< 6 months) CAR T-cell persistence. (C) Top enriched pathways among up-regulated and down-regulated differentially expressed genes between patients with long-term vs failed CAR T-cell persistence in T_EM and T_EFF. (D) Top 20 predicted TFs associated with long CAR T-cell persistence in T_EM and T_EFF (FDR < 0.05). (E) Transcriptional regulatory network of the top 10 predicted TFs in (D) and top 50 DEGs.

Integrative bulk and single-cell profiling of pre-manufacture T-cell populations reveals factors mediating long-term persistence of CAR T-cell therapy

Cancer Discov. ;11(9):2186-2199.
Figure 8

(a) Dealer login. (b) Updating car maintenance record in blockchain. (c) Successful record update. (d) Search for car history including maintenance record.

Implementation of a Distributed Framework for Permissioned Blockchain-Based Secure Automotive Supply Chain Management

Sensors (Basel). 2022 Oct;22(19):7367.
Figure 7C4-27z and C4opt-27z RNA CAR T cells reduce the progression of solid ovarian cancer in vivo

A. NSG mice bearing solid SKOV3 tumor were treated with on intratumuoral injection of 2 × 10⁷ CAR+ T cells on day 21 (loading dose) followed by a lower maintenance dose of 10⁷ CAR+ T cells on days 28 and 35. B–C. Tumor growth was measured weekly by SKOV3 fLUC⁺ bioluminescence (B) and by caliper measurement. C4-27z and C4opt-27z CAR T lymphocytes treated significantly reduced tumor bioluminescence and volume compared to animals receiving no treatment (2-way ANOVA, p < .001). D. CD4⁺ and CD8⁺ C4-27z and C4opt-27z CAR T cells were initially present at low numbers in peripheral circulation, suggesting FRα-specific CAR T cell migration to specific tumor locales (student t test, p < .01 - .001). E. Repeat administration of C4-27z and C4opt-27z CAR T cells resulted in CD4⁺ and CD8⁺ T cell expansion in peripheral blood during therapy (student t test, p < .01 - .001) F. C4-27z and C4opt-27z CAR T cells are not eliminated after treatment and continue to proliferate despite losing CAR reactivity (student t test, p < .05 - .01).

Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor

Oncotarget. 2015 Oct 6;6(30):28911-28928.